About
Respinova has developed the PulseHaler, a noninvasive technology that aims to treat the core pathophysiology of chronic obstructive pulmonary disorder (COPD). The PulseHalers proprietary multi-frequency air pressure pulse technology is an easy-to-use treatment intended for patients diagnosed with COPD of all severity stages. The companys technology was successfully validated in two clinical studies. The first study demonstrated PulseHalers ability to improve the lung function, exercise capacity, and quality of life of COPD patients. The second study demonstrated the technologys ability to deliver drugs more effectively to the lung periphery. The PulseHaler stands alongside leading COPD drugs in managing the disease and enhancing the patients functional capacity and quality of life and has the potential to become a standard of care in COPD management. The commercialization of PulseHaler was co-funded by the European Unions Horizon 2020 program. The device was granted an FDA 510(k) clearance in April 2021.